Literature DB >> 25227211

Toward the harmonization of result presentation for the eosin-5'-maleimide binding test in the diagnosis of hereditary spherocytosis.

Linda Hunt1, David Greenwood, Hermann Heimpel, Nigel Noel, Alastair Whiteway, May-Jean King.   

Abstract

BACKGROUND: The eosin-5'-maleimide (EMA) Binding test measures reduced mean channel fluorescence (MCF) reading of EMA-labeled red cells (EMA-RBCs) from patients with hereditary spherocytosis (HS). Reporting test results can be either in the actual MCF reading or as a ratio by normalization of the test MCF result to the mean MCF value of six normal controls. The latter format has potential for universal reporting.
METHODS: We analyzed three years' archival MCF data from HS and non-HS patient groups for establishment of reference ranges of ratios for normal adults and HS. A prospective study used FC500 and FACS Canto II cytometers to analyze contemporaneously EMA-RBCs from several patient groups and normal donors. Statistical analyses of the prospective data determined the cut-off values, and the sensitivity and specificity for HS respectively for the MCF and the ratio result presentations. The effect of using fewer than six normal controls for the ratio denominator was explored.
RESULTS: The FC500 gave a mean ratio of 0.782 (SD=0.086) in HS patients with an optimal cut-off ratio of 0.918 (98.7% specificity, 95.6% sensitivity), and gray area ratio of 0.868-0.918. The Canto II gave a mean ratio of 0.774 (SD=0.085) with an optimal cut-off ratio of 0.925 (97.1% specificity and 100% sensitivity), and gray area ratio of 0.859-0.925.
CONCLUSION: Harmonization of result presentation is feasible with no apparent constraint by instrument design. Interpretation of gray-area data requires an assessment of patient's clinical presentation and family history or performing a family study.
© 2014 Clinical Cytometry Society.

Entities:  

Keywords:  EMA binding test; flow cytometry; harmonization of EMA test; hereditary spherocytosis

Mesh:

Substances:

Year:  2014        PMID: 25227211     DOI: 10.1002/cyto.b.21187

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  9 in total

1.  Flow Cytometric Eosin-5'-Maleimide Test is a Sensitive Screen for Hereditary Spherocytosis.

Authors:  Preethi S Chari; Sujay Prasad
Journal:  Indian J Hematol Blood Transfus       Date:  2017-12-06       Impact factor: 0.900

Review 2.  Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia.

Authors:  Hee Won Chueh; Sang Mee Hwang; Ye Jee Shim; Jae Min Lee; Hee Sue Park; Joon Hee Lee; Youngwon Nam; Namhee Kim; Hye Lim Jung; Hyoung Soo Choi
Journal:  Blood Res       Date:  2022-05-20

3.  Facilitating EMA binding test performance using fluorescent beads combined with next-generation sequencing.

Authors:  Andreas Glenthøj; Christian Brieghel; Amina Nardo-Marino; Richard van Wijk; Henrik Birgens; Jesper Petersen
Journal:  EJHaem       Date:  2021-09-09

Review 4.  Laboratory Approach to Hemolytic Anemia.

Authors:  Manu Jamwal; Prashant Sharma; Reena Das
Journal:  Indian J Pediatr       Date:  2019-12-10       Impact factor: 1.967

5.  Mean corpuscular volume of control red blood cells determines the interpretation of eosin-5'-maleimide (EMA) test result in infants aged less than 6 months.

Authors:  Olga Ciepiela; Anna Adamowicz-Salach; Weronika Bystrzycka; Jan Łukasik; Iwona Kotuła
Journal:  Ann Hematol       Date:  2015-04-25       Impact factor: 3.673

6.  Stability of eosin-5'-maleimide dye used in flow cytometric analysis for red cell membrane disorders.

Authors:  Simmi Mehra; Neetu Tyagi; Pranav Dorwal; Amit Pande; Dharmendra Jain; Ritesh Sachdev; Vimarsh Raina
Journal:  Blood Res       Date:  2015-06-25

Review 7.  The diagnostic protocol for hereditary spherocytosis-2021 update.

Authors:  Yangyang Wu; Lin Liao; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2021-10-24       Impact factor: 2.352

8.  Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis.

Authors:  Shiyue Ma; Lingjian Tang; Chaoli Wu; Hui Tang; Xue Pu; Jinhong Niu
Journal:  Appl Bionics Biomech       Date:  2022-01-28       Impact factor: 1.781

9.  Novel compound heterozygous SPTA1 mutations in a patient with hereditary elliptocytosis.

Authors:  Shiyue Ma; Jinqiu Qin; Aiqiu Wei; Xiaohong Li; Yuanyuan Qin; Lin Liao; Faquan Lin
Journal:  Mol Med Rep       Date:  2018-02-26       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.